Unknown

Dataset Information

0

Efficacy and Safety of Dulaglutide by Baseline HbA1c in Chinese Patients with Type 2 Diabetes: A Post Hoc Analysis.


ABSTRACT: INTRODUCTION:To evaluate the efficacy and safety of dulaglutide 0.75 and 1.5 mg in patients with type 2 diabetes mellitus (T2DM) by baseline glycated hemoglobin (HbA1c)?

SUBMITTER: Yu M 

PROVIDER: S-EPMC7192976 | biostudies-literature | 2020 May

REPOSITORIES: biostudies-literature

altmetric image

Publications

Efficacy and Safety of Dulaglutide by Baseline HbA1c in Chinese Patients with Type 2 Diabetes: A Post Hoc Analysis.

Yu Miao M   Yuan Guo Yue GY   Zhang Bin B   Wu Hai Ya HY   Lv Xiao Feng XF  

Diabetes therapy : research, treatment and education of diabetes and related disorders 20200410 5


<h4>Introduction</h4>To evaluate the efficacy and safety of dulaglutide 0.75 and 1.5 mg in patients with type 2 diabetes mellitus (T2DM) by baseline glycated hemoglobin (HbA1c) < 8.5% or ≥ 8.5% after 26 weeks of treatment.<h4>Methods</h4>Assessment of the Weekly AdministRation of dulaglutide in Diabetes (AWARD) China 1 (CHN1) study (NCT01644500, n = 556) included patients on dulaglutide vs. glimepiride who were treatment naïve or on monotherapy but discontinued therapy. AWARD-CHN2 (NCT01648582,  ...[more]

Similar Datasets

| S-EPMC7509013 | biostudies-literature
| S-EPMC7192982 | biostudies-literature
| S-EPMC6944837 | biostudies-literature
| S-EPMC6848683 | biostudies-literature
| S-EPMC8776932 | biostudies-literature
| S-EPMC8063250 | biostudies-literature
| S-EPMC7670946 | biostudies-literature
| S-EPMC6852007 | biostudies-literature
| S-EPMC6084353 | biostudies-literature
| S-EPMC7376772 | biostudies-literature